Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 10,07 € (+645,93%). La mediana è 4,50 € (+233,33%).
| Acquista |
11 |
| Mantieni |
0 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Actinium shows strong preclinical efficacy of ATNM-400 in NSCLC models
Actinium presented preclinical data on ATNM-400, an Actinium-225–linked radioconjugate for non‑small cell lung cancer, at the Society of Nuclear Medicine annual meeting. In KRAS‑mutant models, ATNM-400 as monotherapy outperformed the KRAS inhibitors sotorasib and adagrasib and enhanced their tumor‑cell killing when combined. In EGFR‑mutant models, ATNM-400 achieved 75% tumor growth inhibition versus 40% for osimertinib; the combination produced complete tumor regressions in all treated mice. The target antigen was detectable in approximately 98% of NSCLC tumors, and investor assessments see upside potential for the stock despite high cash burn. » Altro su de.investing.com
Actinium presents preclinical data on ATNM-400 and Actimab‑A at AACR on April 21
Actinium will present posters with unpublished preclinical data on April 21 at the AACR annual meeting for ATNM-400 (an Ac‑225 radioconjugate for solid tumors) and Actimab‑A (a therapy for AML/MDS). ATNM-400 showed activity in models of metastatic, castration‑resistant prostate cancer as well as non‑small cell lung and breast cancer; Actimab‑A data illuminate a mechanism described as “transcriptional reprogramming.” The presentations are part of the session block “Radiopharmaceutical Platforms for Theranostic Precision Oncology”; Actimab‑A is being co‑developed with the National Cancer Institute. The stock is trading near its 52‑week low and the company reports high liquidity. » Altro su de.investing.com
Actinium Pharmaceuticals rises after promising preclinical data on ATNM-400
Actinium Pharmaceuticals' stock rose about 3.7% after the presentation of new preclinical data on ATNM-400 at the San Antonio Breast Cancer Symposium 2025. The Actinium-225–based antibody‑radioconjugate showed strong antitumor activity in several breast cancer models, including hormone receptor‑positive, triple‑negative and treatment‑resistant tumors, with a favorable tolerability profile. The data demonstrated irreversible double‑strand DNA breaks caused by the alpha‑emitter payload; Actinium plans to advance ATNM-400 as a monotherapy and in combinations and sees potential also in prostate and non‑small‑cell lung cancer. » Altro su de.investing.com
Actinium: ATNM-400 shows efficacy in preclinical models of therapy-resistant breast cancer subtypes
Actinium presents preclinical data demonstrating a tumor-inhibiting effect of ATNM-400 in hormone receptor–positive, HER2-positive and triple-negative breast cancer models that are resistant to tamoxifen or trastuzumab. In certain models, ATNM-400 produced tumor growth inhibition of more than 100% at higher doses. The Actinium-225 antibody–radioconjugate uses alpha particles, targets proteins that are overexpressed in association with resistance, and is designed to reduce the risk of unwanted lung toxicity. The data will be presented on December 11, 2025, at the San Antonio Breast Cancer Symposium; earlier preclinical results also showed promising effects in lung and prostate cancer. » Altro su de.investing.com
Actinium Pharmaceuticals: shareholders elect directors and ratify audit and compensation proposals
At the 2025 annual meeting, Ajit S. Shetty and June S. Almenoff were re-elected as Class III directors until the 2028 annual meeting. Shareholders ratified CBIZ as the independent registered public accounting firm for fiscal year 2025 and approved, in a non-binding advisory vote, the named executive officer compensation. In addition, a three-year cycle was established for future advisory votes on executive compensation. A total of 15,494,573 common shares were represented; all proposals submitted to a vote were approved. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | giugno 2026 | YoY |
|---|---|---|
| Ricavi | 30,67 Mln | - |
| Utile lordo | 30,67 Mln | - |
| Utile netto | 24,45 Mln | 518,94% |
| EBITDA | 24,66 Mln | 535,48% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 46,9 Mln € |
Numero di azioni | 31,44 Mln |
Massimo/minimo a 52 settimane | 1,56 € - 0,67 € |
| Dividendi | No |
Beta | 0,02 |
Rapporto P/E | 4,56 |
Rapporto PEG | 0,02 |
Rapporto P/B | 1,70 |
Rapporto P/S | 1,47 |
Profilo aziendale
Actinium Pharmaceuticals, Inc., una società biofarmaceutica in fase clinica, si concentra sullo sviluppo e la commercializzazione di terapie per il trapianto di midollo osseo (BMT) o un tipo di terapia cellulare e per altre terapie con cellule adottive. Il suo principale candidato prodotto, I-131 apamistamab (Iomab-B), è in un importante studio clinico di Fase III per la leucemia mieloide acuta recidivante o refrattaria in pazienti anziani, per il condizionamento in vista del BMT; e uno studio di Fase I con una terapia con cellule T CAR mirata a CD19 insieme al Memorial Sloan Kettering Cancer Center. La società offre inoltre programmi di sviluppo clinico e preclinico che utilizzano più isotopi, tra cui Actinium-225, Iodio-131 e Lutezio-177, diretti a diversi bersagli oncologici validati, tra cui CD45, CD33, CD38, CD47, HER2 e HER3, per il condizionamento mirato prima di terapie cellulari e geniche, come il trapianto di midollo osseo, e per terapie oncologiche come agenti singoli o in combinazione con altre modalità terapeutiche. Ha una collaborazione con Astellas Pharma, Inc. per sviluppare teranostici per indicazioni di tumori solidi; con EpicentRx, Inc., che si concentra su una nuova radioterapia mirata immunoterapica anti-CD47; e con AVEO Oncology, che si concentra sullo sviluppo di un ARC mirato a HER3 per tumori solidi. La società è stata costituita nel 2000 ed ha sede a New York, New York.
| Nome | Actinium Pharmaceuticals |
| CEO | Sandesh C. Seth |
| Sede centrale | New York City,
ny Stati Uniti |
| Sito web | |
| Industria | Prodotti chimici |
| Quotazione in borsa | 27/12/2012 |
| Dipendenti | 27 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
AMEX | ATNM |
Frankfurt | 7AY1.F |
Düsseldorf | 7AY1.DU |